اوٹسوکا پاکستان کا منافع مالی سال 26 میں 1,605٪ اضافے سے 472 ملین روپے رہا، ڈیویڈنڈ سے گریز۔ Otsuka Pakistan FY26 profit skyrockets 1,605% YoY to PKR 472M (EPS: Rs 39.02); skips dividend due to debt repayment.
Ex-date is not in this summary yet; check book closure in the official PSX attachment below.
اوٹسوکا پاکستان لمیٹڈ نے مالی سال 26 کے لیے اپنے شاندار سالانہ مالیاتی نتائج کا اعلان کیا ہے جس میں کمپنی کے خالص منافع (PAT) میں 1,605 فیصد کا غیر معمولی اضافہ ریکارڈ کیا گیا ہے۔ تاہم، کمپنی نے بیرونی قرضوں کے بھاری بوجھ کے باعث شیئر ہولڈرز کے لیے کسی ڈیویڈنڈ کا اعلان نہیں کیا۔
مالیاتی موازنہ (بمقابلہ گزشتہ سال)
| پیرامیٹر | مالی سال 26 (ہزار روپے) | مالی سال 25 (ہزار روپے) | تبدیلی (%) |
|---|---|---|---|
| نیٹ سیلز | 4,111,107 | 3,779,518 | +8.77% |
| فروخت کی لاگت | (2,652,203) | (2,916,119) | -9.05% |
| مجموعی منافع | 1,458,904 | 863,399 | +68.97% |
| دیگر آمدنی | 291,669 | 128,290 | +127.35% |
| مالیاتی لاگت | (11,199) | (5,903) | +89.72% |
| ٹیکس سے قبل منافع | 771,766 | 107,540 | +617.65% |
| ٹیکس کے بعد خالص منافع | 472,125 | 27,677 | +1,605.8% |
اہم مثبت عوامل:
- غیر ضروری ادویات کی قیمتوں پر کنٹرول ختم ہونے سے کمپنی کو اپنی لاگت کے مطابق قیمتیں بڑھانے کی لچک ملی۔
- خام مال کی موثر خریداری اور پیداواری صلاحیت میں بہتری کی وجہ سے مجموعی منافع کا مارجن (Gross Margin) 22.84٪ سے بڑھ کر 35.49٪ ہو گیا۔
- جاپانی ہولڈنگ کمپنی سے حاصل کردہ قرضے پر روپیہ مضبوط ہونے کی وجہ سے 140.8 ملین روپے کا فاریکس ایکسچینج گین حاصل ہوا۔
خدشات اور چیلنجز:
- کمپنی پر جاپانی ہولڈنگ کمپنی کا 942.7 ملین روپے (550 ملین جاپانی ین) کا قلیل مدتی قرضہ واجب الادا ہے، جس کی وجہ سے کمپنی منافع بخش ہونے کے باوجود ڈیویڈنڈ جاری نہیں کر سکی۔
- افغانستان کی سرحد پر تجارتی بندش اور خطے میں جیو پولیٹیکل تناؤ برآمدی سرگرمیوں کو متاثر کر سکتا ہے۔
مستقبل کا آؤٹ لک:
کمپنی طبی غذائیت (Clinical Nutrition) اور اینٹرل نیوٹریشن (Enteral Nutrition) جیسے نئے شعبوں میں مصنوعات متعارف کروا رہی ہے جن کی فروخت میں اضافے کی قوی امید ہے۔ اگلے 3 سے 5 سالوں میں جاپانی قرضوں کی بتدریج واپسی کمپنی کو مالی دباؤ سے نجات دلائے گی۔
خالص آمدنی میں شاندار اضافہ اور EPS کا 39.02 روپے تک پہنچنا کمپنی کی زبردست آپریشنل کارکردگی کی عکاسی کرتا ہے۔ اگرچہ ڈیویڈنڈ نہ ملنا قلیل مدتی طور پر مایوس کن ہو سکتا ہے، لیکن قرضوں کی کمی سے طویل مدتی سرمایہ کاروں کو شیئر ہولڈر ویلیو میں زبردست اضافہ حاصل ہوگا۔ کارکردگی مجموعی طور پر انتہائی مثبت ہے۔
Otsuka Pakistan Limited has announced an outstanding financial turnaround for the fiscal year ended June 30, 2026. Driven by price de-control on non-essential products and gross margin expansion, Profit After Tax (PAT) surged by over 1,600%. However, the company skipped dividends to conserve cash for foreign loan repayment obligations.
Financial Income Statement (PKR in \'000)
| Financial Metric | FY26 (Current) | FY25 (Previous) | YoY Change (%) |
|---|---|---|---|
| Revenue from Contract with Customers | 4,111,107 | 3,779,518 | +8.77% |
| Cost of Sales | (2,652,203) | (2,916,119) | -9.05% |
| Gross Profit | 1,458,904 | 863,399 | +68.97% |
| Other Income | 291,669 | 128,290 | +127.35% |
| Finance Cost | (11,199) | (5,903) | +89.72% |
| Profit Before Taxation | 771,766 | 107,540 | +617.65% |
| Profit After Taxation | 472,125 | 27,677 | +1,605.84% |
Key Financial Drivers:
- Gross Margin Expansion: Gross margins significantly improved to 35.49% (vs 22.84% last year) due to the pricing flexibility allowed on non-essential pharmaceutical products and optimized raw material sourcing.
- Foreign Exchange Gain: The company recorded a substantial net exchange gain of PKR 140.8 million on a foreign currency loan due to favorable rupee movement.
- Effective Cost Containment: Despite inflation, the cost of sales declined by 9.05% due to improved supply chain efficiencies.
Risks & Concerns:
- High Foreign Debt: The company carries a massive unsecured foreign currency loan from its related Japanese parent entity, Otsuka Pharmaceutical Factory, Inc., totaling PKR 942.7 million (JPY 550 million). The priority to pay back this debt resulted in skipping dividends.
- Underutilized Capacity: Market oversupply led to underutilized plant capacity for major product lines (IV solutions and plastic ampoules).
Opportunities & Business Outlook:
Otsuka is leveraging its position by expanding product offerings in high-margin Clinical Nutrition (CN) and Enteral Nutrition (EN) segments (e.g., Neo-Mune, Once-Dialyze). Pricing flexibility allows the company to offset future inflationary pressures, and plans are in place to clear outstanding foreign debts over the next 3-5 years.
OTSU has demonstrated an excellent turnaround with an EPS of PKR 39.02. Although skipping dividends might dampen short-term retail sentiment, the fundamental balance sheet strengthening through debt reduction and stellar operational profits is highly positive for long-term investors.
Otsuka Pakistan Limited has announced an outstanding financial turnaround for the fiscal year ended June 30, 2026. Driven by price de-control on non-essential products and gross margin expansion, Profit After Tax (PAT) surged by over 1,600%. However, the company skipped dividends to conserve cash for foreign loan repayment obligations.
Financial Income Statement (PKR in \'000)
| Financial Metric | FY26 (Current) | FY25 (Previous) | YoY Change (%) |
|---|---|---|---|
| Revenue from Contract with Customers | 4,111,107 | 3,779,518 | +8.77% |
| Cost of Sales | (2,652,203) | (2,916,119) | -9.05% |
| Gross Profit | 1,458,904 | 863,399 | +68.97% |
| Other Income | 291,669 | 128,290 | +127.35% |
| Finance Cost | (11,199) | (5,903) | +89.72% |
| Profit Before Taxation | 771,766 | 107,540 | +617.65% |
| Profit After Taxation | 472,125 | 27,677 | +1,605.84% |
Key Financial Drivers:
- Gross Margin Expansion: Gross margins significantly improved to 35.49% (vs 22.84% last year) due to the pricing flexibility allowed on non-essential pharmaceutical products and optimized raw material sourcing.
- Foreign Exchange Gain: The company recorded a substantial net exchange gain of PKR 140.8 million on a foreign currency loan due to favorable rupee movement.
- Effective Cost Containment: Despite inflation, the cost of sales declined by 9.05% due to improved supply chain efficiencies.
Risks & Concerns:
- High Foreign Debt: The company carries a massive unsecured foreign currency loan from its related Japanese parent entity, Otsuka Pharmaceutical Factory, Inc., totaling PKR 942.7 million (JPY 550 million). The priority to pay back this debt resulted in skipping dividends.
- Underutilized Capacity: Market oversupply led to underutilized plant capacity for major product lines (IV solutions and plastic ampoules).
Opportunities & Business Outlook:
Otsuka is leveraging its position by expanding product offerings in high-margin Clinical Nutrition (CN) and Enteral Nutrition (EN) segments (e.g., Neo-Mune, Once-Dialyze). Pricing flexibility allows the company to offset future inflationary pressures, and plans are in place to clear outstanding foreign debts over the next 3-5 years.
OTSU has demonstrated an excellent turnaround with an EPS of PKR 39.02. Although skipping dividends might dampen short-term retail sentiment, the fundamental balance sheet strengthening through debt reduction and stellar operational profits is highly positive for long-term investors.